Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (28652)	4/4/1999 10:23:00 PM
From: RXGOLF	Respond to of 32384

Good evening Cacaito, Thanks once again for sharing your expertise with the board. You have enlightened me with your knowledge, and I know of few others that have this same understanding of certain situations in the biotech field. Good luck and happy Easter, Greg

To: Cacaito who wrote (28652)	4/4/1999 10:57:00 PM
From: J Stone	Respond to of 32384

I also appreciated your feedback. I'm curious as to how much Panretin and Ontak LGND has sold so far. Considering they had built up inventory of Ontak prior to its final approval, I'm hoping that the original inventory has been sold or at least distributed. Thanks again for your insights. Jeff

To: Cacaito who wrote (28652)	4/4/1999 11:23:00 PM
From: Spekulatius	Read Replies (1) \| Respond to of 32384

Thanks for your response.I found the link to be extremely helpful. I indeed found some papers regarding RFS2000,conducted from the Stehlin Institute. It will be interesting to see the first sales numbers for Panretin and Ontak. Panretin may have an advantage over Ontak and Nipent, since its an orally administered drug. I still see the Seragen acquisition as wasted money.the fact that 500M$ have been spend in research does not mean anything - only the marginal Ontak drug came out of Sereagen research adnI am not aware that Seragen research projects are continued by LGND. LGND has enough trouble to fund its own pipeline.